Abstract：
UNASSIGNED: To analyze the efficacy of laser panretinal photocoagulation in combination with Lucentis treatment on patients with retinal arterial macroaneurysm and investigate more effective novel therapy options to treat retinal arterial macroaneurysm.
UNASSIGNED: This study was conducted in the Pediatric department of Chongqing Aier Hospital between October 2016 and October 2020, and a total of 62 inpatients were enrolled for the study. Patients were randomly organized into two groups, an \'observation group\' with patients receiving combinational treatment of laser panretinal photocoagulation and Lucentis, and a \'control group\' with patients treated by only laser panretinal photocoagulation, were allotted. Though a comparative statistical analysis, the clinical outcomes and adverse effects on both groups, including their best corrected visual acuity, central macular thickness, intraocular pressure, and required number of laser treatments before and after treatments, were investigated. Also prognosis associated factors for patient\'s visual function, were analyzed.
UNASSIGNED: The clinical efficacy of the combinational treatment of laser panretinal photocoagulation and Lucentis was better than single laser panretinal photocoagulation treatment, accompanied by decreased incidence of adverse reactions (P < .05). For a combinational treatment, the observation group showed improved best corrected visual acuity and reduced central macular thickness and intraocular pressure, including fewer laser treatments (P < .05). Also, a better prognostic quality of life score; (measured as physical function, mental state, visual function, and social activity ability of patients), was observed for a combinational treatment than that of laser panretinal photocoagulation treatment (P < .05).
UNASSIGNED: Laser panretinal photocoagulation combined with lucentis can deliver with reduced incidence of adverse effects compared to laser panretinal photocoagulation treatment and hence can more effectively contribute to retinal rehabilitation of patients with retinal arterial macroaneurysm.
UNASSIGNED: This study was conducted in the Pediatric department of Chongqing Aier Hospital between October 2016 and October 2020, and a total of 62 inpatients were enrolled for the study. Patients were randomly organized into two groups, an \'observation group\' with patients receiving combinational treatment of laser panretinal photocoagulation and Lucentis, and a \'control group\' with patients treated by only laser panretinal photocoagulation, were allotted. Though a comparative statistical analysis, the clinical outcomes and adverse effects on both groups, including their best corrected visual acuity, central macular thickness, intraocular pressure, and required number of laser treatments before and after treatments, were investigated. Also prognosis associated factors for patient\'s visual function, were analyzed.
UNASSIGNED: The clinical efficacy of the combinational treatment of laser panretinal photocoagulation and Lucentis was better than single laser panretinal photocoagulation treatment, accompanied by decreased incidence of adverse reactions (P < .05). For a combinational treatment, the observation group showed improved best corrected visual acuity and reduced central macular thickness and intraocular pressure, including fewer laser treatments (P < .05). Also, a better prognostic quality of life score; (measured as physical function, mental state, visual function, and social activity ability of patients), was observed for a combinational treatment than that of laser panretinal photocoagulation treatment (P < .05).
UNASSIGNED: Laser panretinal photocoagulation combined with lucentis can deliver with reduced incidence of adverse effects compared to laser panretinal photocoagulation treatment and hence can more effectively contribute to retinal rehabilitation of patients with retinal arterial macroaneurysm.
摘要：
■分析激光全视网膜光凝联合Lucentis治疗对视网膜动脉大动脉瘤患者的疗效，并探讨更有效的治疗视网膜动脉大动脉瘤的新疗法选择。
本研究于2016年10月至2020年10月在重庆爱尔医院儿科进行，共纳入62名住院患者。患者随机分为两组,观察组患者接受激光全视网膜光凝和Lucentis联合治疗，和“对照组”，患者仅接受激光全视网膜光凝治疗，被分配。通过比较统计分析,两组的临床结果和不良反应，包括他们最好的矫正视力，黄斑中心厚度,眼内压,以及治疗前后所需的激光治疗次数，被调查了。患者视觉功能的预后相关因素，进行了分析。
■激光全视网膜光凝和Lucentis联合治疗的临床疗效优于单一激光全视网膜光凝治疗，不良反应发生率降低(P<0.05)。对于组合治疗，观察组改善了最佳矫正视力,降低了黄斑中心厚度和眼压,包括较少的激光治疗（P<0.05）。此外，更好的预后生活质量评分；(衡量为身体功能，精神状态,视觉功能,和患者的社会活动能力)，观察到联合治疗比激光全视网膜光凝治疗（P<0.05）。
■与激光全视网膜光凝治疗相比，激光全视网膜光凝联合lucentis可以降低不良反应的发生率，因此可以更有效地促进视网膜动脉大动脉瘤患者的视网膜康复。
本研究于2016年10月至2020年10月在重庆爱尔医院儿科进行，共纳入62名住院患者。患者随机分为两组,观察组患者接受激光全视网膜光凝和Lucentis联合治疗，和“对照组”，患者仅接受激光全视网膜光凝治疗，被分配。通过比较统计分析,两组的临床结果和不良反应，包括他们最好的矫正视力，黄斑中心厚度,眼内压,以及治疗前后所需的激光治疗次数，被调查了。患者视觉功能的预后相关因素，进行了分析。
■激光全视网膜光凝和Lucentis联合治疗的临床疗效优于单一激光全视网膜光凝治疗，不良反应发生率降低(P<0.05)。对于组合治疗，观察组改善了最佳矫正视力,降低了黄斑中心厚度和眼压,包括较少的激光治疗（P<0.05）。此外，更好的预后生活质量评分；(衡量为身体功能，精神状态,视觉功能,和患者的社会活动能力)，观察到联合治疗比激光全视网膜光凝治疗（P<0.05）。
■与激光全视网膜光凝治疗相比，激光全视网膜光凝联合lucentis可以降低不良反应的发生率，因此可以更有效地促进视网膜动脉大动脉瘤患者的视网膜康复。
